Insider Trading News

DocuSign CEO Allan C. Thygesen sells $1.8 million in stock

By Investing.com2 min readInvesting.com
DocuSign CEO Allan C. Thygesen sells $1.8 million in stockDocuSign CEO Allan C. Thygesen sells $1.8 million in stock

DocuSign CEO Allan C. Thygesen sells $1.8 million in stock

Allan C. Thygesen, President and CEO of DocuSign, Inc. (NASDAQ:DOCU), sold a total of 26,250 shares of common stock on October 1, 2026. The transactions amounted to a total value of $1,818,929, with shares sold at prices ranging from $68.53 to $69.98. These sales were conducted pursuant to a Rule 10b5-1 trading plan.

The sales were executed in three separate blocks. One transaction involved 7,475 shares, sold at prices ranging from $67.89 to $68.87. Another 13,598 shares were sold at prices ranging from $68.89 to $69.88. The final block consisted of 5,177 shares, which were sold at prices ranging from $69.89 to $70.16.

Following these reported transactions, Mr. Thygesen directly holds 166,801 shares of DocuSign common stock.The insider sale comes as DocuSign shares have surged approximately 43% over the past six months, currently trading at $69.01 with a market capitalization of $13 billion. According to InvestingPro analysis, the stock remains undervalued relative to its Fair Value, suggesting potential upside for investors. The company maintains impressive gross profit margins of nearly 80% and continues to demonstrate revenue growth of 8.6%. For deeper insights into DocuSign’s valuation and access to exclusive ProTips, visit InvestingPro’s most undervalued stocks.

In other recent news, Docusign Inc. reported notable developments following its second-quarter performance. The company achieved revenue growth of 9.4%, driven by digital sales improvements, new Identity and Access Management (IAM) bookings, higher expansion rates, and better gross retention. This performance led to several firms adjusting their price targets for Docusign. Citi and Baird both raised their price targets to $72, citing customer growth and positive annual recurring revenue trends, respectively. Morgan Stanley increased its price target to $75, highlighting Docusign’s advancements in its IAM product and fiscal 2027 guidance adjustments. Meanwhile, Wells Fargo adjusted its target to $60, focusing on the company’s IAM growth. Needham reiterated a Hold rating, acknowledging the strong quarterly results. These updates reflect a general acknowledgment of Docusign’s recent strategic progress and financial performance.